Jacc: Heart Failure

• 

  Publication Venue For

  • Heart Failure Site-Based Research in the United States: Results of the Heart Failure Society of America Research Network Survey..  7:431-438. 2019
  • Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease..  7:371-382. 2019
  • GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population. 2019
  • Heart Failure Fake News: How Do We Distinguish the Truth?.  7:363. 2019
  • Reframing Global Variation in Heart Failure Trials: Thinking Beyond Location on the Map..  7:347-349. 2019
  • Requiem for a Heavyweight: Ejection Fraction as a Prognostic Biomarker..  7:318-320. 2019
  • Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry..  7:350-358. 2019
  • Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?.  7:267-271. 2019
  • Primary Prevention of Heart Failure in Women..  7:181-191. 2019
  • Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation..  7:250-257. 2019
  • Cardiac Dysfunction Among People Living With HIV: A Systematic Review and Meta-Analysis..  7:98-108. 2019
  • NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF..  7:158-168. 2019
  • History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure..  7:47-55. 2019
  • Potassium Abnormalities Across the Spectrum of Heart Failure..  7:77-79. 2019
  • Reply: Vaccination in Patients With Heart Failure: An Established Recommendation in Patients With Chronic Heart Disease..  7:85. 2019
  • The Urgency of Doing: Addressing Gaps in Use of Evidence-Based Medical Therapy for Heart Failure..  7:22-24. 2019
  • Adiposity and Incident Heart Failure and its Subtypes.  6:999-1007. 2018
  • Aviation Emergencies for Heart Failure Cardiologists: A New Twist to the Heart Team..  6:1047-1048. 2018
  • Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure: The HF-ACTION Trial..  6:1011-1019. 2018
  • Reply: Diuretic Strategies and Renal Dysfunction in Heart Failure With Preserved Ejection Fraction..  6:1050. 2018
  • Aortic Insufficiency During Contemporary Left Ventricular Assist Device Support: Analysis of the INTERMACS Registry..  6:951-960. 2018
  • COAPTing Heart Failure Physicians, Interventional Cardiologists, and CardioThoracic Surgeons: A New Opportunity for Patients..  6:967-968. 2018
  • Caregivers of Patients Considering a Destination Therapy Left Ventricular Assist Device and a Shared Decision-Making Intervention: The DECIDE-LVAD Trial..  6:904-913. 2018
  • Is it Time to Get More Aggressive With Aortic Valve Insufficiency During LVAD Implantation?.  6:961-963. 2018
  • Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus..  6:813-822. 2018
  • Combating Acute Heart Failure in the Arena: Lessons From the ROPA-DOP Trial..  6:871-873. 2018
  • Depression in Heart Failure: Beyond a SADHART.  6:885-886. 2018
  • Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial..  6:833-843. 2018
  • Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect?.  6:831-832. 2018
  • Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial.  6:859-870. 2018
  • Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure..  6:844-855. 2018
  • A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation..  6:771-779. 2018
  • HVAD: The ENDURANCE Supplemental Trial..  6:792-802. 2018
  • It Is Time to Discuss Dying..  6:790-791. 2018
  • Politically Correct Heart Failure Research in America to Avoid Geographic Variation.  6:805-806. 2018
  • Predicting Prognosis in Heart Failure: Important, But Easier Said Than Done ^∗.  6:754-756. 2018
  • HFpEF: From Early Observations to Worldwide Awareness.  6:718-719. 2018
  • Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials..  6:619-632. 2018
  • Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope..  6:698-700. 2018
  • Cardiovascular Drug Pricing: Less Innovation for More Access?.  6:613-614. 2018
  • Will Biomarkers Succeed as a Surrogate Endpoint in Heart Failure Trials?^∗.  6:570-572. 2018
  • Dying With Dignity and Heart Failure.  6:536-537. 2018
  • Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure..  6:465-473. 2018
  • Revascularization for Heart Failure: Can We Do Better?.  6:527-529. 2018
  • Traveling the Interstices of Data Sharing..  6:533-535. 2018
  • Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction..  6:388-397. 2018
  • What's One More Day?.  6:438. 2018
  • "Time Is Muscle" in Acute Heart Failure: Critical Concept or Fake News?.  6:295-297. 2018
  • Changing the Research Culture in the United States.  6:344-345. 2018
  • Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey.  6:273-285. 2018
  • Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial..  6:298-307. 2018
  • Heart Failure Health Care 2018: Challenges and Opportunities.  6:262-263. 2018
  • Post-Myocardial Infarction Heart Failure..  6:179-186. 2018
  • Reply.  6:267-267. 2018
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial..  6:96-104. 2018
  • Are We Approaching Chronotropy (In)competently?.  6:114-116. 2018
  • Cardiac Rehabilitation After Ventricular Assist Device Implantation: A Worthwhile Exercise?.  6:140-142. 2018
  • Smartphone, Mom, and HFpEF.  6:176. 2018
  • Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure.  6:65-70. 2018
  • I Don’t Care How Low My BNP Is, I Want to Feel Good.  6:82-83. 2018
  • Happy 50th Birthday, Cardiac Transplantation: Happy 5th Birthday, JACC: Heart Failure..  5:946-947. 2017
  • Implantable Cardioverter-Defibrillators in Patients With Left Ventricular Assist Devices: On Trial and in Need of a Trial..  5:927-929. 2017
  • Goodbye Mihai: We Will Miss You..  5:848-849. 2017
  • Realizing the Potential of Metabolomics in Heart Failure: Signposts on the Path to Clinical Utility..  5:833-836. 2017
  • Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure..  5:735-742. 2017
  • Q&A With the JACC: Heart Failure Editor-in-Chief: Marking the 5-Year Milestone..  5:758-759. 2017
  • The Risk of Stroke on Left Ventricular Assist Device Support: Steady Gains or Stalled Progress?.  5:712-714. 2017
  • Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study..  5:724-734. 2017
  • America and Apple Pie: How Do We Change the American Health Care System?.  5:686-687. 2017
  • Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure..  5:663-671. 2017
  • Medical Management of Patients With a Left Ventricular Assist Device for the Non-Left Ventricular Assist Device Specialist.  5:622-631. 2017
  • Medical Management of Patients With a Left Ventricular Assist Device for the Non-Left Ventricular Assist Device Specialist..  5:621-631. 2017
  • Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types..  5:689. 2017
  • Does Institutional Memory Matter?.  5:616. 2017
  • A Decade With Editorial Mentors: The Day They Dropped the Mic..  5:541-542. 2017
  • Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction..  5:507-517. 2017
  • Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction..  5:483-493. 2017
  • Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients The ROADMAP Study 2-Year Results.  5:518-527. 2017
  • Breaking Bad: The Heartbreak of Drug Abuse..  5:446-448. 2017
  • Development of Acute Decompensated Heart Failure Therapies: Is the Journey Over?.  5:464-465. 2017
  • A Novel Rehabilitation Intervention for Older Patients With Acute Decom ensated Heart Failure The REHAB-HF Pilot Study.  5:359-366. 2017
  • A Novel Rehabilitation Intervention for Older Patients With Acute Decompensated Heart Failure: The REHAB-HF Pilot Study..  5:359-366. 2017
  • Acute Heart Failure: Alternatives to Hospitalization..  5:329-336. 2017
  • High Heart Failure Readmission Rates: Is It the Health System's Fault?.  5:393. 2017
  • Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy.  5:388-392. 2017
  • Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy..  5:388-392. 2017
  • Data Sharing From the Editors' Perspective: Our Hope With Limitations..  5:314-315. 2017
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF)..  5:305-309. 2017
  • Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure..  5:287-296. 2017
  • Moving Beyond the Walls of the Clinic: Opportunities and Challenges to the Future of Telehealth in Heart Failure..  5:297-304. 2017
  • Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis..  5:280-286. 2017
  • Reply: Factors That May Affect Body Change During and After Hospitalization for Acute Heart Failure..  5:311-312. 2017
  • Can Vaccinations Improve Heart Failure Outcomes? Contemporary Data and Future Directions.  5:195-203. 2017
  • Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions..  5:194-203. 2017
  • Easy to Predict, Difficult to Prevent..  5:226-228. 2017
  • Is Salt Bad for You?.  5:238-239. 2017
  • JACC: Heart Failure Series: FDA in the 21st Century: Focus on Nutrition and Heart Failure Prevention..  5:229-231. 2017
  • Return on Investment in Implantable Devices: Cardiac Resynchronization Therapy in Mildly Symptomatic Heart Failure..  5:213-215. 2017
  • 21st Century Cures: A Step Forward for Patients With Heart Failure..  5:154. 2017
  • FDA in the 21st Century: Focus on Tobacco Policies and Heart Failure Prevention..  5:152-153. 2017
  • Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet..  5:107-109. 2017
  • Optimism, Pessimism, and Pragmatism: Musings on the Cost of Medical Innovation..  5:120-122. 2017
  • Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes Findings From the ASCEND-HF Trial.  5:3-13. 2017
  • Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial..  5:1-13. 2017
  • Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience..  5:71-72. 2017
  • Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis..  5:28-38. 2017
  • Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation..  5:44-52. 2017
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development..  5:67-70. 2017
  • Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes..  4:935-946. 2016
  • Not Your Mother's FDA..  4:978. 2016
  • Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations..  4:923-931. 2016
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Heart Failure Devices..  4:974-977. 2016
  • Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From ASCEND-HF. 2016
  • Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. 2016
  • Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial..  4:860-869. 2016
  • Left Bundle Branch Block: Is it "Unsafe at Any Speed"?.  4:904-906. 2016
  • Peer Review of Peer Review: Somewhere Over the Rainbow..  4:907-908. 2016
  • Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community..  4:808-815. 2016
  • The International Olympic Games: Heart Teams and Heart Failure..  4:826-827. 2016
  • Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease?.  4:689-697. 2016
  • Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure..  4:726-735. 2016
  • The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy..  4:749-755. 2016
  • The Mentor’s Mentor.  4:759-759. 2016
  • Can Academic Cardiology Divisions Survive?.  4:687-688. 2016
  • Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION..  4:617-624. 2016
  • Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program..  4:649-661. 2016
  • Brain Natriuretic Peptide Treatment and Heart Failure Prevention: Reliving the Mistakes of the Past or Charting a New Course for the Future?.  4:548-550. 2016
  • Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction..  4:559-566. 2016
  • Promoting Transparency in Trials: Lessons From the COMPANION Investigators..  4:536-538. 2016
  • The Year in Heart Failure Review 2015 to 2016.  4:603-604. 2016
  • Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial..  4:591-599. 2016
  • Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps..  4:419-427. 2016
  • Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction..  4:464-472. 2016
  • Prolonged QRS in Heart Failure With Preserved Ejection Fraction: Risk Marker and Therapeutic Target?.  4:487-489. 2016
  • Social Media: Can It Reduce Heart Failure Events?.  4:514-515. 2016
  • Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study..  4:380-388. 2016
  • Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry.  4:348-356. 2016
  • Are We Really in Love With Old Therapies? 2016
  • Why Negative Trials Are Positive for Heart Failure Patients..  4:329-330. 2016
  • A Machine Without an Owner's Manual..  4:218-219. 2016
  • I Lost a Friend From HFpEF: William Anlyan, MD, Chancellor Emeritus and Duke University Trustee..  4:230-231. 2016
  • Utility of Patient-Reported Outcome Instruments in Heart Failure..  4:165-175. 2016
  • Death of the Heart Failure Clinical Investigator: Molecules and Receptors Win Nobel Prizes, Clinical Investigation Improves Survival..  4:162-163. 2016
  • Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial..  4:109-115. 2016
  • When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF..  4:106-108. 2016
  • Air Pollution in Patients With Heart Failure: Lessons From a Mechanistic Pilot Study of a Filter Intervention..  4:65-67. 2016
  • Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure..  4:42-49. 2016
  • Back to the Future With Intravenous Diuretics: Reinvigorating an Old Treatment Through New Care Settings..  4:9-11. 2016
  • Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure..  4:68-77. 2016
  • Reply: Is Pump the Answer to Heart Failure With Preserved Ejection Fraction?.  4:93. 2016
  • Why Dr. Robert Califf's Nomination for Commissioner of the Food and Drug Administration Is Good for Heart Failure Patients..  4:90-91. 2016
  • Heart Failure "End Result Cards": Solid B..  3:1001-1002. 2015
  • Bundle Up for Value-Based Heart Failure Care..  3:931-932. 2015
  • Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy..  3:906-916. 2015
  • Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)..  3:777-785. 2015
  • Fibroblast Growth Factor-23 Fans the Flames of Heart and Kidney Failure..  3:840-842. 2015
  • Physician-Leaders: A Call for Cardiovascular Specialists to Step Up..  3:843-844. 2015
  • The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies..  3:818-828. 2015
  • What's Harder: Seeing a Doctor or Reducing Readmissions?.  3:774-776. 2015
  • "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction..  3:661-669. 2015
  • Changing the Carburetor Without Changing the Plugs: The Intersection of Stock Car Racing With Mechanically Assisted Circulation..  3:712-714. 2015
  • What Is a Life Worth?: A Tribute to Dr. William Little, a Pioneer in the Understanding of Heart Failure With Preserved Ejection Fraction..  3:734-735. 2015
  • Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure..  3:629-636. 2015
  • Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries..  3:579-590. 2015
  • Light Chains and the Failing Heart: Important Mechanistic Link or Fifty Shades of Gray?.  3:626-628. 2015
  • The Globalization of Heart Failure Research..  3:657-658. 2015
  • Why We Respect Randomized Controlled Clinical Trials in Heart Failure..  3:576-577. 2015
  • Cardiac Resynchronization Therapy in the Autumn of Life..  3:505-507. 2015
  • Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?.  3:497-504. 2015
  • Time for Recognition..  3:508-509. 2015
  • Medical editors' grand rounds: a discussion of timely topics and editorial emergencies..  3:422-423. 2015
  • Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies..  3:395-403. 2015
  • Reading RVUs: How can we meet the informational needs of cardiologists?.  3:340-341. 2015
  • Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure)..  3:245-252. 2015
  • Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure)..  3:193-201. 2015
  • Hop, skip, and jump: do we need phase II cardiovascular clinical trials?.  3:273-274. 2015
  • Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure.  3:97-107. 2015
  • Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure..  3:97-107. 2015
  • Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure..  3:136-145. 2015
  • Primary prevention implantable cardioverter-defibrillators and survival in older women..  3:159-167. 2015
  • War and peace: the role of medical journals in the discussion of conflict..  3:192. 2015
  • Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling..  3:68-69. 2015
  • Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial..  3:40-49. 2015
  • Conflict of interest and transparency: are the headlights misaligned?.  3:94. 2015
  • Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, Fluid Homeostasis, Inflammation, and Renal Injury.  3:30-39. 2015
  • Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury..  3:30-39. 2015
  • Left Atrial Decompression Pump for Severe Heart Failure With Preserved Ejection Fraction: Theoretical and Clinical Considerations.  3:275-282. 2015
  • Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction..  3:50-58. 2015
  • The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease..  3:9-16. 2015
  • What's Harder: Seeing a Doctor or Reducing Readmissions?^*.  3:774-776. 2015
  • BAG3 protein in advanced-stage heart failure..  2:673-675. 2014
  • Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials..  2:623-629. 2014
  • Precision and predictive medicine: lessons learned from our oncology colleagues..  2:671. 2014
  • Race, common genetic variation, and therapeutic response disparities in heart failure..  2:561-572. 2014
  • Reply: predicting sudden cardiac death in heart failure..  2:673. 2014
  • Are models better than cardiologists?: An analysis of risk prediction in heart failure..  2:536-537. 2014
  • Can we now find the needle in the haystack?.  2:474-476. 2014
  • Charting a roadmap for heart failure biomarker studies..  2:477-488. 2014
  • Chronic counterpulsation devices for heart failure..  2:534-535. 2014
  • Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure..  2:457-465. 2014
  • Does low bone mineral density cause a broken heart?.  2:390-391. 2014
  • Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure)..  2:335-343. 2014
  • Heart failure: where the paths cross..  2:427. 2014
  • Atrial fibrillation and sudden cardiac death: is heart failure the middleman?.  2:228-229. 2014
  • Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure..  2:260-268. 2014
  • Developing therapies for heart failure with preserved ejection fraction: current state and future directions..  2:97-112. 2014
  • Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)..  2:159-165. 2014
  • Meta-analysis bouillabaisse..  2:201-202. 2014
  • Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives..  2:1-14. 2014
  • Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b)..  2:84-92. 2014
  • Design of design papers..  2:95-96. 2014
  • Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure..  2:65-72. 2014
  • Outcomes of medicare beneficiaries with heart failure and atrial fibrillation..  2:41-48. 2014
  • Atrial fibrillation and sudden cardiac death: Is heart failure the middleman?.  2:228-229. 2014
  • Charting a roadmap for heart failure biomarker studies.  2:477-488. 2014
  • Does Low Bone Mineral Density Cause a Broken Heart?.  2:390-391. 2014
  • Editorial Mentorship.  2:321-322. 2014
  • Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure).  2:335-343. 2014
  • Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: Results from a combined analysis of 4 randomized clinical trials.  2:623-629. 2014
  • Rationale and design of theguide-it study: Guiding evidence based therapy usingbiomarker intensified treatment inheart failure.  2:458-465. 2014
  • It is time to exercise change for heart failure..  1:549-550. 2013
  • The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial..  1:488-496. 2013
  • Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States..  1:523-530. 2013
  • Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy..  1:480-487. 2013
  • JACC: Heart Failure fellows program: training the next generation..  1:458. 2013
  • Associations Between Use of the Hospitalist Model and Quality of Care and Outcomes of Older Patients Hospitalized for Heart Failure.  1:445-453. 2013
  • Associations between use of the hospitalist model and quality of care and outcomes of older patients hospitalized for heart failure..  1:445-453. 2013
  • The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results..  1:400-408. 2013
  • DUCCS and SWANS: when U.S. site-based research was highly successful..  1:366-367. 2013
  • Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)..  1:308-314. 2013
  • Do we really need more biomarkers?.  1:270-271. 2013
  • Left bundle branch block predicts better survival in women than men receiving cardiac resynchronization therapy: long-term follow-up of ∼ 145,000 patients..  1:237-244. 2013
  • Surfing the biomarker tsunami at JACC: heart failure..  1:213-215. 2013
  • Validated, electronic health record deployable prediction models for assessing patient risk of 30-day rehospitalization and mortality in older heart failure patients..  1:245-251. 2013
  • Better late than never: a welcome publication of tardy clinical trial results..  1:112-114. 2013
  • Dead letter office..  1:181-182. 2013
  • Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing)..  1:142-148. 2013
  • Why JACC: heart failure?.  1:91. 2013
  • Thyroid function in heart failure and impact on mortality..  1:48-55. 2013
  • Heart failure complicating non-st-segment elevation acute coronary syndrome: Timing, predictors, and clinical outcomes.  1:223-229. 2013
  • Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta₁ 389 Arg/Gly Adrenergic Receptor Polymorphism 2013
  • Prevention of atrial fibrillation by bucindolol is dependent on the beta₁ 389 Arg/Gly adrenergic receptor polymorphism.  1:338-344. 2013
  • Racial/ethnic differences in b-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: Findings from get with the guidelines-heart failure.  1:345-352. 2013
  • Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. 2017
  • Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. 2016
  • Surgical Treatment for Ischemic Heart Failure (STICH) Trial: Mode of Death Results. 2013